Neuronetics (STIM) News and press releases

Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS

19 Jan 23

News, Penny Stocks, Health Care, Contracts, General

Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay

10 Jan 23

News, Penny Stocks, Health Care, Legal, Movers, Trading Ideas, General

Neuronetics's Return On Capital Employed Overview

6 Dec 22

Earnings

12 Health Care Stocks Moving In Friday's After-Market Session

2 Dec 22

Movers

Stocks That Hit 52-Week Lows On Thursday

1 Dec 22

Options

During Thursday's session, 108 stocks hit new 52-week highs.

12 Health Care Stocks Moving In Thursday's Intraday Session

17 Nov 22

Movers

Neuronetics Q3 EPS $(0.28) Beats $(0.42) Estimate, Sales $16.50M Beat $15.02M Estimate

8 Nov 22

Earnings, News

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.42) by 33.33 percent. This is a 9.68 percent increase over losses of $(0.31) per share from the

Earnings Scheduled For November 8, 2022

8 Nov 22

Earnings

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Jan 23

Press Releases

MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

17 Jan 23

Health Care, Press Releases

MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

29 Dec 22

News, Management, Press Releases

MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 Dec 22

Press Releases

MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category

5 Dec 22

Health Care, Press Releases

MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference

21 Nov 22

News, Press Releases

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations

14 Nov 22

Health Care, Press Releases, General

MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

9 Nov 22

Health Care, Markets, Press Releases

MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life

Neuronetics Reports Third Quarter 2022 Financial and Operating Results

8 Nov 22

Earnings, Press Releases

MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they